Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...

The company has increased its payouts over the past five years despite significant challenges.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

In new data released by the Food and Drug Administration on Wednesday, Pfizer said vaccine booster shots would restore protection against COVID-19 to up to 95% in real-world settings, CNBC and ABC ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.

How many profitable, large-cap healthcare companies pay a dividend yield of over 5%? Only one. Pfizer (NYSE: PFE) checks off all the boxes. It's profitable, raking in earnings of over $9.4 billion in ...